From: Timely HAART initiation may pave the way for a better viral control
ID | Therapy†| Elapsed days ‡ | Days on therapy | Days out therapy | At diagnosis* | At first interruption | ||||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  | CD4 | CD8 | vRNA | CD4 | CD8 | vRNA |
Pt 07 | AZT, 3TC | 300 | 1303 | 606 | 463 | 2498 | 34000 | 614 | 3101 | 9154 |
Pt 12 | D4T, 3TC, SQV | 26 | 1117 | 89 | 422 | 754 | 62000 | 601 | 948 | < 50 |
Pt 16 | AZT, ddC, Rit | 9 | 1803 | 66 | 116 | 1170 | 990000 | 483 | 1165 | < 50 |
Pt 17 | AZT, 3TC | 49 | 1872 | 412 | 51 | 1155 | 110000 | 693 | 1359 | 150 |
Pt 18 | AZT, ddl | 268 | 1615 | 558 | 340 | 994 | 35000 | 989 | 1172 | < 50 |
Pt 19 | AZT, 3TC | 393 | 819 | 206 | 559 | 1230 | 70319 | 616 | 825 | < 50 |
Pt 20 | AZT, 3TC | 15 | 2503 | 21 | 235 | 877 | 230000 | 566 | 1246 | < 50 |
Pt 22 | D4T, 3TC | 0 | 1807 | 64 | 290 | Â | 140000 | 1334 | Â | < 50 |
Pt 23 | AZT, 3TC | 483 | 2109 | 248 | 409 | 734 | 47000 | 686 | 572 | < 50 |
Pt 25 | D4T,3TC, IDV | 22 | 1661 | 625 | 383 | 809 | 37000 | 896 | 1208 | < 50 |
Pt 26 | AZT, 3TC | 38 | 841 | 1150 | 540 | 1256 | 16000 | 719 | 640 | < 50 |
Pt 27 | AZT,3TC | 10 | 1885 | 50 | 332 | Â | 2800 | 636 | Â | < 50 |
Pt 28 | AZT,3TC,EFV | 0 | 3131 | 373 | 556 | Â | 1900 | 752 | Â | < 50 |
Pt 29 | AZT,3TC,Lop/rit | 21 | 1950 | 69 | 483 | Â | 150000 | 1233 | Â | 100 |
Pt 31 | AZT,3TC,IDV | 0 | 1255 | 109 | 574 | 1625 | 7900 | 813 | 640 | < 50 |
Pt 32 | AZT,3TC,IDV | 0 | 1472 | 160 | 393 | Â | 1335 | 1235 | Â | < 50 |
Pt 33 | D4T, 3TC | 407 | 523 | 66 | 479 | 494 | 473 | 705 | 450 | < 50 |
Pt 34 | ddl, D4T, NVP | 13 | 2207 | 54 | 493 | 1628 | 230000 | 907 | 943 | < 50 |
Pt 38 | AZT,3TC,LPV | 0 | 1460 | 270 | 481 | 1156 | 20000 | 534 | 964 | < 50 |
Pt 39 | AZT,3TC,NVP | 64 | 2734 | 767 | 539 | Â | 41000 | 859 | Â | < 50 |
Pt 41 | AZT,3TC,Lop/rit | 62 | 428 | 89 | 200 | Â | 135000 | 848 | Â | < 50 |